A clinical resource highlighting key information about ADSTILADRIN (nadofaragene firadenovec-vncg)
Resources
Information and Support for ADSTILADRIN
Download practice resources
Instructions for Use
A summary of storage, preparation, administration, and disposal information for ADSTILADRIN
How to Order ADSTILADRIN
A step-by-step guide on how to order ADSTILADRIN, including product codes
Patient Enrollment Form
Once you have identified your patient for ADSTILADRIN, please use this enrollment form to begin the ordering process
Submit your enrollment form at ferringaccesssupport.com
ADSTILADRIN Product Replacement Policy
A document that outlines the procedure for returning ADSTILADRIN product, including eligibility criteria and requirements
Download patient materials
Getting Started With ADSTILADRIN for Patients
A patient-friendly overview of the ADSTILADRIN clinical story as well as what patients should expect before and after treatment
Download reimbursement resources
Medicare Part B Reimbursement Guide
Information about Medicare Part B reimbursement
ADSTILADRIN Copay Program Leave Behind
An overview of the ADSTILADRIN Copay Program. Eligible, commercially insured patients may pay as little as $100* for each ADSTILADRIN prescription
ADSTILADRIN Pass-Through Leave Behind
A quick summary of the pass-through status for ADSTILADRIN, including coding details
ADSTILADRIN Average Sales Price (ASP) Leave Behind
A leave behind that outlines the establishment of the ASP for ADSTILADRIN
Watch videos
ADSTILADRIN in Practice
Neal Shore, MD, FACS, discusses key information about ADSTILADRIN treatment, including preparation and administration
Hear From a Board-Certified Urologist
Lawrence Karsh, MD, FACS, shares his experience from the ADSTILADRIN clinical trials
ADSTILADRIN Is a Localized Treatment for Localized Tumors
Watch the mechanism of action video to learn more about how ADSTILADRIN works
*Available only for patients who meet eligibility requirements. Program does not cover the cost of administration, office visits, or any associated costs. Terms and conditions apply. Offer expires 12/31/24.
Sign Up to Receive Information and Updates on ADSTILADRIN (nadofaragene firadenovec-vncg)
Form ToggleImportant Safety Information
INDICATION
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.
WARNINGS AND PRECAUTIONS:
- Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
- Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.
DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.
USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.
ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).
You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.
Please see full Prescribing Information for ADSTILADRIN.